Pub. Date : 2014 Sep
PMID : 24496315
7 Functional Relationships(s)Download |
Sentence | Compound Name | Protein Name | Organism |
| 1 | In this model, HES coadministration with Alternaria/OVA suppressed early IL-33 release, innate lymphoid cell (ILC) production of IL-4, IL-5, and IL-13, and localized eosinophilia. | Helium | serine (or cysteine) peptidase inhibitor, clade B, member 1, pseudogene | Mus musculus |
| 2 | Upon OVA challenge, type 2 ILC (ILC2)/Th2 cytokine production and eosinophilia were diminished in HES-treated mice. | Helium | serine (or cysteine) peptidase inhibitor, clade B, member 1, pseudogene | Mus musculus |
| 3 | Administration of recombinant IL-33 at sensitization with Alternaria/OVA/HES abrogated HES suppression of OVA-specific responses at challenge, indicating that suppression of early Alternaria-induced IL-33 release could be central to the anti-allergic effects of HES. | Helium | serine (or cysteine) peptidase inhibitor, clade B, member 1, pseudogene | Mus musculus |
| 4 | Administration of recombinant IL-33 at sensitization with Alternaria/OVA/HES abrogated HES suppression of OVA-specific responses at challenge, indicating that suppression of early Alternaria-induced IL-33 release could be central to the anti-allergic effects of HES. | Helium | serine (or cysteine) peptidase inhibitor, clade B, member 1, pseudogene | Mus musculus |
| 5 | Administration of recombinant IL-33 at sensitization with Alternaria/OVA/HES abrogated HES suppression of OVA-specific responses at challenge, indicating that suppression of early Alternaria-induced IL-33 release could be central to the anti-allergic effects of HES. | Helium | serine (or cysteine) peptidase inhibitor, clade B, member 1, pseudogene | Mus musculus |
| 6 | Administration of recombinant IL-33 at sensitization with Alternaria/OVA/HES abrogated HES suppression of OVA-specific responses at challenge, indicating that suppression of early Alternaria-induced IL-33 release could be central to the anti-allergic effects of HES. | Helium | serine (or cysteine) peptidase inhibitor, clade B, member 1, pseudogene | Mus musculus |
| 7 | Administration of recombinant IL-33 at sensitization with Alternaria/OVA/HES abrogated HES suppression of OVA-specific responses at challenge, indicating that suppression of early Alternaria-induced IL-33 release could be central to the anti-allergic effects of HES. | Helium | serine (or cysteine) peptidase inhibitor, clade B, member 1, pseudogene | Mus musculus |